Ian Bouligny, MD
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | LSU Health Shreveport School of Medicine, Shreveport, LA, US, Medicine, MD |
| 2013 | Louisiana State University, Baton Rouge, LA, US, Biological Sciences, BS |
Postgraduate Training
| 2023-2024 | Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2020-2023 | Fellowship, VCU Massey Cancer Center, Richmond, VA |
| 2017-2020 | Residency, Internal Medicine, Wake Forest Baptist Health, Winston-Salem, North Carolina |
Experience & Service
Administrative Appointments/Responsibilities
Project ERIS Team Leader, Department of Hematology & Oncology, VCU, Richmond, VA, 2022 - 2023
Leukemia Clinical Research Team Leaders, Department of Leukemia, VCU, Richmond, VA, 2021 - 2023
Resident Research Committee Leaders, Department of Hematology & Oncology, Wake Forest Hematology & Oncology, Winston-Salem, North Carolina, 2019 - 2020
Internal Medicine Residency Accommodations Partnership, Department of Internal Medicine, Wake Forest, Winston-Salem, North Carolina, 2018 - 2020
Accommodations Partnership, Wake Forest School of Medicine, Winston-Salem, North Carolina, 2018 - 2020
Vice President of the Deaf and Hard-of-Hearing Club, LSU Baton Rouge, Baton Rouge, LA, 2013
Other Appointments/Responsibilities
Project Eris Team Leader, Leukemia, VCU Hematology & Oncology, Richmond, VA, 2023 - 2023
Leukemia Clinical Research Team Leader, VCU Hematology & Oncology, Richmond, VA, 2021 - 2023
Resident Research Committee Leader, Wake Forest Hematology & Oncology, Winston-Salem, NC, 2019 - 2020
Accommodations Partnership, Wake Forest School of Medicine, Winston-Salem, NC, 2018 - 2020
Residency Accommodations Partnership, Wake Forest Internal Medicine, Winston-Salem, NC, 2018 - 2020
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Bazinet, A, Bataller Torralba, A, Kadia, TM, Daver, N, Short, NJ, Yilmaz, M, Sasaki, K, DiNardo, C, Borthakur, G, Issa, GC, Bouligny, IM, Pierce, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer 131(6), 2025. e-Pub 2025. PMID: 40097915.
- Bouligny IM, DiNardo CD. Oral decitabine-cedazuridine in acute myeloid leukaemia. Br J Haematol 205(5):1674-1676, 2024. e-Pub 2024. PMID: 39313925.
- Murray GF, Bouligny IM, Ho T, Gor J, Zacholski K, Wages NA, Grant S, Maher KR. Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia. Eur J Haematol 114(1):98-104, 2024. e-Pub 2024. PMID: 39315590.
- Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Ho T, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia. Med Oncol 41(3):80, 2024. e-Pub 2024. PMID: 38396145.
- Bouligny IM, Murray G, Ho T, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia. Res Sq, 2023. e-Pub 2023. PMID: 37398154.
- Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia. EJHaem 4(2):381-392, 2023. e-Pub 2023. PMID: 37206255.
- Bouligny IM, Maher KR, Grant S. Augmenting Venetoclax Activity Through Signal Transduction in AML. J Cell Signal 4(1):1-12, 2023. e-Pub 2023. PMID: 36911757.
- Bouligny IM, Mehta V, Isom S, Ellis LR, Bhave RR, Howard DS, Lyerly S, Manuel M, Dralle S, Powell BL, Pardee TS. Efficacy of 10-day decitabine in acute myeloid leukemia. Leuk Res 103:106524, 2021. e-Pub 2021. PMID: 33640708.
Other Articles
- Bouligny IM, Maher KR, Grant S Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022. Cancers (Basel) 15(13), 2023. PMID: 37444402.
- Bouligny IM, Maher KR, Grant S Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. Blood Rev 57:100996, 2023. PMID: 35989139.
- Maher KR, Bouligny IM, Yeager AM Prevention and management of infections after exposure to ionizing radiation. J Radiol Prot 41(4), 2021. PMID: 34265748.
Abstracts
- Tran V, Bouligny IM, Murray G, Patel T, Doyel M, Boron J, Gor J, Hang Y, Ho T, Zacholski K, Venn CM, Alnimer YM, Wages N, Grant S, Maher KR. FLAG-IDA or venetoclax in previously treated TP53mut acute myeloid leukemia. ASCO 41(16). e-Pub 2023.
- Murray G, Bouligny IM, Patel T, Doyel M, Boron J, Tran V, Gor J, Hang Y, Ho T, Zacholski K, Venn CM, Alnimer YM, Wages N, Grant S, Maher KR. Gilteritinib or venetoclax in relapsed or refractory FLT3mut acute myeloid leukemia. ASCO 41(16). e-Pub 2023.
- Murray G, Bouligny IM, Patel T, Doyel M, Boron J, Tran V, Gor J, Hang Y, Ho T, Zacholski K, Venn CM, Alnimer YM, Wages N, Grant S, Maher KR. IDH inhibitors or chemotherapy in relapsed or refractory IDHmut acute myeloid leukemia. ASCO 41(16). e-Pub 2023.
- Doyel M, Bouligny IM, Murray G, Patel T, Boron J, Tran V, Gor J, Hang Y, Ho T, Zacholski K, Venn CM, Alnimer YM, Wages N, Grant S, Maher KR. The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine. ASCO 41(16). e-Pub 2023.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Back in JAK - Real-World Analysis of JAKmut AML. Blood 140(1):11812–11813, 2022. e-Pub 2022.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. CPX-351 Appears Superior to 7+3 in Adverse-Risk AML and AML-MRC. ASH 140(1):11745–11746. e-Pub 2022.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Healthcare Disparities Among Minorities Treated with Venetoclax and Hypomethylating Agents in AML. ASH 140(1):13305–13306. e-Pub 2022.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. IDH1/2mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML. ASH 140(1):6335–6336. e-Pub 2022.
- Tran V, Bouligny IM, Alnimer YM, Zacholski K, Venn CM, Ho T, Maher KR. Impact of TKI combination therapy and MRD negativity on outcomes in Philadelphia chromosome-positive ALL: A retrospective, single-center experience. ASCO. e-Pub 2022.
- Zacholski K, Bouligny IM, Venn CM, Tran V, Alnimer YM, Ho T, Maher KR. Analysis of real-world outcomes of IKZFmut in Philadelphia chromosome-positive ALL: A retrospective, single-institution experience. ASCO 40(16). e-Pub 2022.
- Venn CM, Zacholski K, Tran V, Alnimer YM, Ho T, Maher KR, Bouligny IM. Retrospective analysis of toxicities and clinical outcomes with BCR-ABL1 tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. ASCO 40(16). e-Pub 2022.
- Maher KR, Bouligny I. Outcomes stratified by molecular aberration following induction with daunorubicin 60 mg/m2 versus daunorubicin 90 mg/m2 in AML. ASCO 40(16). e-Pub 2022.
- Maher KR, Bouligny I. Molecular stratification of response and survival of venetoclax in combination with hypomethylating agents in AML. ASCO 40(16). e-Pub 2022.
- Bouligny IM, Tran V, Zacholski K, Venn CM, Alnimer YM, Ho T, Maher KR. Retrospective analysis of healthcare disparities in Philadelphia chromosome-positive ALL: A single-institution experience of a large metropolitan area. ASCO 40(16). e-Pub 2022.
- Tran V, Bouligny IM, Zacholski K, Venn CM, Alnimer YM, Ho T, Maher KR. Efficacy and safety of high-intensity versus reduced-intensity induction in Philadelphia chromosome-positive all ineligible for HSCT. ASCO 40(16). e-Pub 2022.
- Alnimer YM, Bouligny IM, Zacholski K, Venn CM, Tran V, Ho T, Maher KR. Efficacy and safety of asparagine-depleting regimens versus HyperCVAD in adults with Philadelphia chromosome-positive B-ALL: A retrospective analysis. ASCO 40(16). e-Pub 2022.
- Bouligny I, Maher KR. Re-induction with venetoclax in combination with hypomethylating agents (HMAs) versus FLAG-IDA in relapsed or refractory AML. ASCO. e-Pub 2022.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML. Blood 140(1):5281–5282, 2022. e-Pub 2022.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Outcomes of FLAG-IDA Versus MEC in Relapsed or Refractory AML. Blood 140(Supplement 1):11742–11743, 2022. e-Pub 2022.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Real-World Safety and Efficacy of Gemtuzumab Ozogamicin in Relapsed or Refractory AML. Blood 140(1):11744, 2022. e-Pub 2022.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Efficacy of Hypomethylating Agents with Venetoclax in TP53mut AML. Blood 140(1):11842–11843, 2022. e-Pub 2022.
- Maher KR, Bouligny I. A Retrospective Comparison of Hypomethylating Agent in Combination with Venetoclax Versus Liposomal Daunorubicin and Cytarabine in Frontline Treatment of Acute Myeloid Leukemia. ASH 138(Supplement 1):2336, 2021.
- Maher KR, Bouligny I. Minority Health Disparities in Acute Myeloid Leukemia: A Metropolitan, Single-Center Retrospective Analysis. ASH 138(Supplement 1):1987, 2021.
- Bouligny I, Maher KR. Outcomes of Induction with Venetoclax in Combination with Decitabine, Azacitidine, or Low-Dose Cytarabine for Treatment of AML: A Real-World Retrospective Analysis. ASH 138(Supplement 1):2335, 2021.
- Bouligny I, Maher KR. Outcomes of High-Intensity Versus Low-Intensity Induction in Elderly Patients with AML: A Retrospective Analysis of Real-World Outcomes. ASH 138(Supplement 1):4386, 2021.
- Bouligny I, Maher KR. Differential Outcomes of Salvage with FLAG-IDA and Venetoclax-Based Regimens in Relapsed and Refractory Acute Myeloid Leukemia. ASH 138(Supplement 1):4424, 2021.
- Bouligny I, Maher KR. The Impact of Molecular and Cytogenetic Clonal Evolution on Survival in Relapsed/Refractory AML. ASH 138(Supplement 1):4452, 2021.
Letters to the Editor
- Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Pemmaraju N, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal R, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39: 524-528, 2025.
- Bouligny IM, Murray G, Ho T, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia. Leuk Res 134: 107370, 2023.
Patient Reviews
CV information above last modified April 24, 2025